Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03243734 · ClinicalTrials.gov registry record · NA
trūFreeze® Palliative Esophageal Cancer
A NA study, sponsored by US Endoscopy Group.
- Completed
- Registry status
- NA
- Development phase
- 49
- Enrollment target
NCT03243734: Completed NA study, sponsored by US Endoscopy Group.
NCT03243734 is a NA study that has completed, run by US Endoscopy Group. The registered enrollment target is 49 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03243734, a NA study, has completed, sponsored by US Endoscopy Group.
- COMPLETED
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
Study Summary
Prospective, open label, non-controlled single arm, multi-center study The primary objective is to study the effects of the trūFreeze® Spray Cryotherapy System in a population of subjects who have been diagnosed with persistent local esophageal cancer and who are not surgical candidates or have completed or declined systemic therapy.
Primary Outcome
Validated Cancer Specific Quality of Life Questionnaire
Interventions
- DEVICE trūFreeze® System spray cryotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2017-11-06 |
| Est. Completion | 2024-03-06 |
| Phase | NA |
What the finished NCT03243734 record still lists
NCT03243734 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which trūFreeze® System spray cryotherapy is the first listed.
NCT03243734 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03243734 about?
NCT03243734 is a clinical study titled "trūFreeze® Palliative Esophageal Cancer". Prospective, open label, non-controlled single arm, multi-center study The primary objective is to study the effects of the trūFreeze® Spray Cryotherapy System in a population of subjects who have been diagnosed with persistent local esophageal cancer and who are not surgical candidates or have comp...
What is the current status of trial NCT03243734?
This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2017-11-06. Estimated completion is 2024-03-06.
What interventions are being tested in trial NCT03243734?
The interventions under investigation include: trūFreeze® System spray cryotherapy (DEVICE).
Who is sponsoring clinical trial NCT03243734?
This trial is sponsored by US Endoscopy Group, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03243734's enrollment target sits among peer trials
49 1379th of 2000 higher than 620 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI